<DOC>
	<DOCNO>NCT02221258</DOCNO>
	<brief_summary>The purpose phase 1 clinical trial evaluate safety subject moderate severe rheumatoid arthritis infusion .</brief_summary>
	<brief_title>Safety FURESTEM-RA Inj . Patients With Moderate Severe Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) chronic progressive autoimmune disease characterize synovial hyperplasia joint damage lead clinically significant functional impairment . In RA , unknown reason , immune cell infiltrate synovium joint produce 'rheumatoid factor ' , prostaglandin , cytokine mediator . It damage joint cartilage , even organ . 80 % RA patient Rheumatoid factor cause high expression ratio auto-antibodies blood . Produced immune complex , immune cell antigen-presenting cell ( include macrophage , B cell , dendritic cell ) activate release cytokine synovial tissue becomes thicken damage . It report synthetic DMARDs ( disease-modifying antirheumatic drug ) include methotrexate ( MTX ) , sulfasalazine biological DMARDs tumor necrosis factor ( TNF ) -α blocker , abatacept rituximab , often combination MTX , effective . But still limited lack loss efficacy certain patient serious complication serious infection malignancy . So , need identify new treatment . FURESTEM-RA Inj . compose allogeneic hUCB-MSC ( human Umbilical Cord Blood derived-Mesenchymal Stem cell ) . hUCB-MSCs mesenchymal stem cell umbilical cord blood . Mesenchymal stem cell well-known immunosuppression , anti-inflammatory ability capable differentiate wide range cell type include osteocyte chondrocytes . Therefore , FURESTEM-RA Inj . huge possibility cell therapy product RA patient .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1. either gender , 1980years old 2 . Subjects must diagnose ACR functional class I. II , III Rheumatoid Arthritis accord 2010 ACR/EULAR criterion least 12 week duration . 3 . Subjects must take DMARDs NSAIDs include methotrexate , sulfasalazine , hydroxychloroquine , leflunomide stable dose within 12 week screen visit willing remain stable dose throughout study 4 . If subject currently administer steroid everyday , steroid dose convert prednisolone oral dose , subject take stable dose ( ≤10mg/day ) 4 week screen visit 5 . Subject moderate severe disease activity ( DAS28ESR &gt; 3.2 ) screen visit 6 . Subject understands voluntarily sign informed consent form 1 . Subjects diagnose ACR function class IV Rheumatoid Arthritis 2 . Subjects cardiovascular disorder , blood dyscrasia , AIDS ( Acquired Immune Deficiency Syndrome ) , rheumatic disease ( Crohn 's disease , systemic lupus erythematosus , lyme disease , psoriatic arthritis , spondylarthropathy , infectious reactive arthritis , reiter 's syndrome , etc . ) 3. subject administer follow biological DMARDs subject administer 1 drug ( Infliximab , Adalimumab , Etanercept , Anakinra , Abatacept ) within 6 month screen visit subject administer Rituximab within 1 year screen visit 4 . Subject history hypersensitivity , heavy metal poisoning , etc . drug compose similar component . 5 . Subject treat intraarticular steroid injection within 4 week screen visit 6 . Subject administer ACTH ( adrenocorticotropic hormone ) agent within 4 week screen visit 7 . Subject undergone administration investigational drug within 30 day screen visit . 8 . Subject disease take medicine prohibit prescription NSAIDs . 9 . Subject need take medicine prohibit take time 10 . Pregnant , breastfeed woman 11 . Subject sever dyshepatia ( Serum creatinine level ≥ 1.7mg/dl ) 12 . Subject severe renal dysfunction ( ALT/AST/bilirubin value ≥ 2 upper limit normal range screen test ) 13 . Any condition PI Judges would make patient unsuitable study participation 14 . Subject experienced stem cell therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Rheumatic Disease</keyword>
	<keyword>RA</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>furestem</keyword>
	<keyword>Umbilical cord Blood</keyword>
	<keyword>hUCB-MSC</keyword>
	<keyword>UCB-MSC</keyword>
</DOC>